Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy..
OBJECTIVES: To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) during the years 2018-2021.
METHODS: We used multivariable regression models to compare viral suppression (VS) [HIV RNA viral load (VL) <50 copies/mL] and the change in CD4 cell counts at 24 and 48 (±12) weeks after initiation with dolutegravir/lamivudine or other first-line ART regimens.
RESULTS: We included 2160 treatment-naive subjects, among whom 401 (18.6%) started with dolutegravir/lamivudine. The remaining subjects started bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) (n = 949, 43.9%), DTG + FTC/tenofovir disoproxil fumarate (TDF) (n = 282, 13.1%), DTG/3TC/abacavir (ABC) (n = 255, 11.8%), darunavir (DRV)/cobicistat(COBI)/FTC/TAF (n = 147, 6.8%) and elvitegravir (EVG)/COBI/FTC/TAF (n = 126, 5.8%). At 24 and 48 weeks after starting dolutegravir/lamivudine, 91.4% and 93.8% of the subjects, respectively, achieved VS. The probability of achieving VS with dolutegravir/lamivudine was not significantly different compared with any other regimen at 24 or 48 weeks, with the exception of a lower chance of achieving VS at 24 weeks for DRV/COBI/FTC/TAF (adjusted OR: 0.47; 95% CI: 0.30-0.74) compared with dolutegravir/lamivudine.For the analysis of treatment-experienced virally suppressed subjects we included 1456 individuals who switched to dolutegravir/lamivudine, among whom 97.4% and 95.5% maintained VS at 24 and 48 weeks, respectively. During the first 48 weeks after dolutegravir/lamivudine initiation, 1.0% of treatment-naive and 1.5% of treatment-experienced subjects discontinued dolutegravir/lamivudine due to an adverse event.
CONCLUSIONS: In this large multicentre cohort, effectiveness and tolerability of dolutegravir/lamivudine were high among treatment-naive and treatment-experienced subjects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 78(2023), 6 vom: 01. Juni, Seite 1423-1432 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suárez-García, Inés [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2T8Q726O95 |
|---|
| Anmerkungen: |
Date Completed 02.06.2023 Date Revised 12.06.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dkad102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356032094 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356032094 | ||
| 003 | DE-627 | ||
| 005 | 20231226065610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkad102 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356032094 | ||
| 035 | |a (NLM)37099559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suárez-García, Inés |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2023 | ||
| 500 | |a Date Revised 12.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. | ||
| 520 | |a OBJECTIVES: To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) during the years 2018-2021 | ||
| 520 | |a METHODS: We used multivariable regression models to compare viral suppression (VS) [HIV RNA viral load (VL) <50 copies/mL] and the change in CD4 cell counts at 24 and 48 (±12) weeks after initiation with dolutegravir/lamivudine or other first-line ART regimens | ||
| 520 | |a RESULTS: We included 2160 treatment-naive subjects, among whom 401 (18.6%) started with dolutegravir/lamivudine. The remaining subjects started bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) (n = 949, 43.9%), DTG + FTC/tenofovir disoproxil fumarate (TDF) (n = 282, 13.1%), DTG/3TC/abacavir (ABC) (n = 255, 11.8%), darunavir (DRV)/cobicistat(COBI)/FTC/TAF (n = 147, 6.8%) and elvitegravir (EVG)/COBI/FTC/TAF (n = 126, 5.8%). At 24 and 48 weeks after starting dolutegravir/lamivudine, 91.4% and 93.8% of the subjects, respectively, achieved VS. The probability of achieving VS with dolutegravir/lamivudine was not significantly different compared with any other regimen at 24 or 48 weeks, with the exception of a lower chance of achieving VS at 24 weeks for DRV/COBI/FTC/TAF (adjusted OR: 0.47; 95% CI: 0.30-0.74) compared with dolutegravir/lamivudine.For the analysis of treatment-experienced virally suppressed subjects we included 1456 individuals who switched to dolutegravir/lamivudine, among whom 97.4% and 95.5% maintained VS at 24 and 48 weeks, respectively. During the first 48 weeks after dolutegravir/lamivudine initiation, 1.0% of treatment-naive and 1.5% of treatment-experienced subjects discontinued dolutegravir/lamivudine due to an adverse event | ||
| 520 | |a CONCLUSIONS: In this large multicentre cohort, effectiveness and tolerability of dolutegravir/lamivudine were high among treatment-naive and treatment-experienced subjects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a dolutegravir |2 NLM | |
| 650 | 7 | |a DKO1W9H7M1 |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a Oxazines |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 3-Ring |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 700 | 1 | |a Alejos, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Hernando, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Viñuela, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Vera García, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Rial-Crestelo, David |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Elías, María Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Albendín Iglesias, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Peraire, Joaquim |e verfasserin |4 aut | |
| 700 | 1 | |a Tiraboschi, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz, Asunción |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Jarrín, Inma |e verfasserin |4 aut | |
| 700 | 0 | |a Cohort of the Spanish HIV/AIDS Research Network (CoRIS) |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Santiago |e investigator |4 oth | |
| 700 | 1 | |a Jarrín, Inma |e investigator |4 oth | |
| 700 | 1 | |a Dalmau, David |e investigator |4 oth | |
| 700 | 1 | |a Navarro, M Luisa |e investigator |4 oth | |
| 700 | 1 | |a González, M Isabel |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Federico |e investigator |4 oth | |
| 700 | 1 | |a Poveda, Eva |e investigator |4 oth | |
| 700 | 1 | |a Iribarren, Jose Antonio |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez, Félix |e investigator |4 oth | |
| 700 | 1 | |a Rubio, Rafael |e investigator |4 oth | |
| 700 | 1 | |a Vidal, Francesc |e investigator |4 oth | |
| 700 | 1 | |a Berenguer, Juan |e investigator |4 oth | |
| 700 | 1 | |a González, Juan |e investigator |4 oth | |
| 700 | 1 | |a Muñoz-Fernández, M Ángeles |e investigator |4 oth | |
| 700 | 1 | |a Jarrín, Inmaculada |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Rava, Marta |e investigator |4 oth | |
| 700 | 1 | |a Izquierdo, Rebeca |e investigator |4 oth | |
| 700 | 1 | |a Del Romero Raposo, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Marco, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Puente, Julián |e investigator |4 oth | |
| 700 | 1 | |a Muñoz-Fernández, M Ángeles |e investigator |4 oth | |
| 700 | 1 | |a Mauleón, Elba |e investigator |4 oth | |
| 700 | 1 | |a Juárez, Roxana |e investigator |4 oth | |
| 700 | 1 | |a Portilla, Joaquín |e investigator |4 oth | |
| 700 | 1 | |a Portilla, Irene |e investigator |4 oth | |
| 700 | 1 | |a Merino, Esperanza |e investigator |4 oth | |
| 700 | 1 | |a García, Gema |e investigator |4 oth | |
| 700 | 1 | |a Agea, Iván |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-Payá, José |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez, Juan Carlos |e investigator |4 oth | |
| 700 | 1 | |a Giner, Livia |e investigator |4 oth | |
| 700 | 1 | |a Reus, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Boix, Vicente |e investigator |4 oth | |
| 700 | 1 | |a Torrus, Diego |e investigator |4 oth | |
| 700 | 1 | |a Pérez, Verónica |e investigator |4 oth | |
| 700 | 1 | |a Portilla, Julia |e investigator |4 oth | |
| 700 | 1 | |a Alemán, María Remedios |e investigator |4 oth | |
| 700 | 1 | |a Hernández, Jehovana |e investigator |4 oth | |
| 700 | 1 | |a Lirola, Ana López |e investigator |4 oth | |
| 700 | 1 | |a García, Dácil |e investigator |4 oth | |
| 700 | 1 | |a Díaz-Flores, Felicitas |e investigator |4 oth | |
| 700 | 1 | |a Alonso, M Mar |e investigator |4 oth | |
| 700 | 1 | |a Pelazas, Ricardo |e investigator |4 oth | |
| 700 | 1 | |a Asensi, Víctor |e investigator |4 oth | |
| 700 | 1 | |a Rivas, M Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Suarez-Zarracina, Tomás |e investigator |4 oth | |
| 700 | 1 | |a Valle-Garay, Eulalia |e investigator |4 oth | |
| 700 | 1 | |a Díaz, Javier |e investigator |4 oth | |
| 700 | 1 | |a Pulido, Federico |e investigator |4 oth | |
| 700 | 1 | |a Rubio, Rafael |e investigator |4 oth | |
| 700 | 1 | |a Bisbal, Otilia |e investigator |4 oth | |
| 700 | 1 | |a Hernando, M Asunción |e investigator |4 oth | |
| 700 | 1 | |a Rial, David |e investigator |4 oth | |
| 700 | 1 | |a de Lagarde, María |e investigator |4 oth | |
| 700 | 1 | |a Arce, Octavio |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Bermejo, Laura |e investigator |4 oth | |
| 700 | 1 | |a Santacreu, Mireia |e investigator |4 oth | |
| 700 | 1 | |a Navarro, Roser |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Candela |e investigator |4 oth | |
| 700 | 1 | |a Iribarren, Jose Antonio |e investigator |4 oth | |
| 700 | 1 | |a Aramburu, M José |e investigator |4 oth | |
| 700 | 1 | |a Camino, Xabier |e investigator |4 oth | |
| 700 | 1 | |a von Wichmann, Miguel Ángel |e investigator |4 oth | |
| 700 | 1 | |a Goenaga, Miguel Ángel |e investigator |4 oth | |
| 700 | 1 | |a Bustinduy, M Jesús |e investigator |4 oth | |
| 700 | 1 | |a Azkune, Harkaitz |e investigator |4 oth | |
| 700 | 1 | |a Ibarguren, Maialen |e investigator |4 oth | |
| 700 | 1 | |a Kortajarena, Xabier |e investigator |4 oth | |
| 700 | 1 | |a Álvarez-Rodriguez, Ignacio |e investigator |4 oth | |
| 700 | 1 | |a Gil, Leire |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Lourdes |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez, Félix |e investigator |4 oth | |
| 700 | 1 | |a Masiá, Mar |e investigator |4 oth | |
| 700 | 1 | |a Robledano, Catalina |e investigator |4 oth | |
| 700 | 1 | |a Padilla, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Abellán, Javier Garcia |e investigator |4 oth | |
| 700 | 1 | |a Mascarell, Paula |e investigator |4 oth | |
| 700 | 1 | |a Adsuar, Araceli |e investigator |4 oth | |
| 700 | 1 | |a Pascual, Rafael |e investigator |4 oth | |
| 700 | 1 | |a Carvajal, Mar |e investigator |4 oth | |
| 700 | 1 | |a Fernández, Marta |e investigator |4 oth | |
| 700 | 1 | |a García, José Alberto |e investigator |4 oth | |
| 700 | 1 | |a Botella, Ángela |e investigator |4 oth | |
| 700 | 1 | |a de la Rica, Alba |e investigator |4 oth | |
| 700 | 1 | |a Ding, Carolina |e investigator |4 oth | |
| 700 | 1 | |a García-Sánchez, Lidia |e investigator |4 oth | |
| 700 | 1 | |a Ena, Nuria |e investigator |4 oth | |
| 700 | 1 | |a Barber, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Agullo, Vanessa |e investigator |4 oth | |
| 700 | 1 | |a Pascual, Reyes |e investigator |4 oth | |
| 700 | 1 | |a Telenti, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Guillén, Lucia |e investigator |4 oth | |
| 700 | 1 | |a López, Leandro |e investigator |4 oth | |
| 700 | 1 | |a Vallejo, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Gonzalo-Jimenez, Nieves |e investigator |4 oth | |
| 700 | 1 | |a Ruiz, Montserrat |e investigator |4 oth | |
| 700 | 1 | |a Galiana, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Muga, Roberto |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 78(2023), 6 vom: 01. Juni, Seite 1423-1432 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:6 |g day:01 |g month:06 |g pages:1423-1432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkad102 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 6 |b 01 |c 06 |h 1423-1432 | ||